Cargando…

Adverse events induced by nivolumab and ipilimumab combination regimens

BACKGROUND: No meta-analysis has assessed the pooled frequencies of adverse events (AEs) induced by concomitant nivolumab plus ipilimumab regimen for anticancer-medications-naïve malignancies. Furthermore, no meta-analysis has compared detailed safety profiles between four doses of nivolumab 3 mg/kg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Somekawa, Kohei, Horita, Nobuyuki, Kaneko, Ayami, Tagami, Yoichi, Fukuda, Nobuhiko, Matsumoto, Hiromi, Namkoong, Ho, Fujiwara, Yu, Minegishi, Kaoru, Fukumoto, Takeshi, Watanabe, Keisuke, Hara, Yu, Kobayashi, Nobuaki, Kaneko, Takeshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Meta-Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841925/ https://www.ncbi.nlm.nih.gov/pubmed/35173819 http://dx.doi.org/10.1177/17588359211058393

Ejemplares similares

Best regimens for treating chemo‐naïve incurable squamous non‐small cell lung cancer with a programmed death‐ligand 1 tumor proportion score of 1%–49%: A network meta‐analysis
por: Fukuda, Nobuhiko, et al.
Publicado: (2021)

The best regimens for chemo-naïve incurable non-squamous non-small cell lung cancer with a programmed death-ligand 1, tumor proportion score 1–49%: a network meta-analysis
por: Fukuda, Nobuhiko, et al.
Publicado: (2021)

Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis
por: Matsumoto, Hiromi, et al.
Publicado: (2023)

The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastases
por: Fukumoto, Takeshi, et al.
Publicado: (2022)

Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial
por: Matsumoto, Hiromi, et al.
Publicado: (2021)

Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis
por: Chen, Hao, et al.
Publicado: (2020)

Regional differences in epidermal growth factor receptor-tyrosine kinase inhibitor therapy in lung cancer treatment using a national database in Japan
por: Matsumoto, Hiromi, et al.
Publicado: (2023)

Diagnostic utility of transbronchial biopsy for Hodgkin's lymphoma: A case study
por: Hoshi, Miki, et al.
Publicado: (2021)

Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis
por: Kobayashi, Nobuaki, et al.
Publicado: (2021)

Hydroxychloroquine and chloroquine for treatment of coronavirus disease 19 (COVID-19): a systematic review and meta-analysis of randomized and non-randomized controlled trials
por: Ebina-Shibuya, Risa, et al.
Publicado: (2021)

Prognostic factors for mortality in invasive pneumococcal disease in adult: a system review and meta-analysis
por: Chen, Hao, et al.
Publicado: (2021)

Current national policies for infant universal bacille Calmette-Guérin vaccination were associated with lower mortality from coronavirus disease 2019
por: Ebina-Shibuya, Risa, et al.
Publicado: (2020)

T‐cell response to phytohemagglutinin in the interferon‐γ release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with non‐small cell lung cancer
por: Kamimaki, Chisato, et al.
Publicado: (2021)

Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival Outcomes
por: Kobayashi, Nobuaki, et al.
Publicado: (2023)

Immunohistochemical markers to diagnose primary squamous cell carcinoma of the lung: a meta-analysis of diagnostic test accuracy
por: Chen, Hao, et al.
Publicado: (2022)

Clinical Features and Risk Factors for Mortality in Hospitalized Older Adults with Pneumonia
por: Fukuda, Nobuhiko, et al.
Publicado: (2021)

Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report
por: Nakamura, Mikako, et al.
Publicado: (2023)

Clinical features of asthma with connective tissue diseases
por: Watanabe, Keisuke, et al.
Publicado: (2023)

Disease control and objective responsive rates in randomized phase II trials evaluating non-first-line chemotherapy for non-small cell lung cancer: a systematic review of 74 trials
por: Matsumoto, Hiromi, et al.
Publicado: (2021)

Nivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC
por: Luo, Yuejun, et al.
Publicado: (2022)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Hazard ratio of progression-free survival is an excellent predictor of overall survival in phase III randomized controlled trials evaluating the first-line chemotherapy for extensive-disease small-cell lung cancer
por: Chen, Hao, et al.
Publicado: (2020)

Elderly sarcoidosis in Japan
por: Masumoto, Nami, et al.
Publicado: (2022)

Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan
por: Horita, Nobuyuki, et al.
Publicado: (2015)

Genetic model selection for a case–control study and a meta-analysis
por: Horita, Nobuyuki, et al.
Publicado: (2015)

Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial
por: Horita, Nobuyuki, et al.
Publicado: (2020)

Severe eosinophilia and subsequent dermatologic immune‐related adverse event with squamous cell carcinoma antigen elevation induced by nivolumab and ipilimumab
por: Matsumoto, Takeshi, et al.
Publicado: (2022)

The Extent of Honeycombing on Computed Tomography Cannot Predict the Treatment Outcome of Patients with Acute Exacerbations of Interstitial Lung Disease
por: Nishikawa, Yurika, et al.
Publicado: (2021)

Clinical importance of serum heme oxygenase-1 measurement in patients with acute exacerbation of idiopathic pulmonary fibrosis triggered by coronavirus disease 2019
por: Hara, Yu, et al.
Publicado: (2022)

ILD-GAP Combined with the Charlson Comorbidity Index Score (ILD-GAPC) as a Prognostic Prediction Model in Patients with Interstitial Lung Disease
por: Fujii, Hiroaki, et al.
Publicado: (2023)

Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma
por: Danno, Tetsuya, et al.
Publicado: (2021)

Diagnostic test accuracy of D-dimer for acute aortic syndrome: systematic review and meta-analysis of 22 studies with 5000 subjects
por: Watanabe, Hiroki, et al.
Publicado: (2016)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Inhaled Corticosteroid and Secondary Glaucoma: A Meta-analysis of 18 Studies
por: Ishii, Mai, et al.
Publicado: (2021)

Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer
por: Ushio, Ryota, et al.
Publicado: (2021)

Assessment of diagnostic utility of serum hemeoxygenase-1 measurement for acute exacerbation of interstitial pneumonias
por: Kata, Yuki, et al.
Publicado: (2022)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

The triple therapy for chronic obstructive pulmonary disease increases the risk of pneumonias compared to the dual-bronchodilator therapy
por: Watanabe, Keisuke, et al.
Publicado: (2021)

The Effectiveness and Safety of Long-Term Macrolide Therapy for COPD in Stable Status: A Systematic Review and Meta-Analysis
por: Nakamura, Kazunori, et al.
Publicado: (2023)

Non‐small cell lung cancer with mesenchymal–epithelial transition gene exon 14 skipping mutation treated with crizotinib
por: Katakura, Seigo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_75ert2tquiec75gi0thp8dagh3